NCT05749588 2026-04-16
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
Fudan University
Phase 2 Recruiting
Clinical Trials
9 trialsNCT06955169 2026-04-16
MOMENTUM-1
RTOG Foundation, Inc.
Phase 2 Recruiting
NCT04485559 2026-04-13
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
University of California, San Francisco
Phase 1 Suspended
NCT07340541 2026-04-13
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT01167530 2026-04-06
RAD001
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Completed
NCT06382948 2026-04-03
ADELA
MedSIR
Phase 3 Recruiting
NCT00819546 2026-03-25
RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT05843253 2026-03-20
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
NCT03950609 2026-03-19
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting